Kyriakie Sarafoglou, Yesica Mercado Munoz, Charles Sukin, Aida Lteif, Jennifer Kyllo, Bradley S Miller, O Yaw Addo, Deborah Merke
{"title":"疾病特异性生长图对先天性肾上腺增生儿童的重要性。","authors":"Kyriakie Sarafoglou, Yesica Mercado Munoz, Charles Sukin, Aida Lteif, Jennifer Kyllo, Bradley S Miller, O Yaw Addo, Deborah Merke","doi":"10.1210/clinem/dgaf554","DOIUrl":null,"url":null,"abstract":"<p><strong>Background: </strong>Children with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency typically have height, weight and BMI growth patterns that differ from the general population due to increased androgen and/or glucocorticoid exposures. With the recent surge in the development of new therapies, CAH-specific growth charts are needed to evaluate the effectiveness of these new treatments.</p><p><strong>Methods: </strong>Retrospective data from patients aged 0-20 years with classic CAH, confirmed by hormonal testing and/or CYP21A2 genotyping, from two large clinical databases were analyzed. Specialized charts were developed using the Lamda-Mu-Sigma semi-parametric modeling method to generate CAH-specific percentile curves from 0-20 years. Nodal-point analyses were conducted to assess differences in incremental growth at 4, 8, 12, 16 and 20 years of age relative to CDC-2000 normative charts using one-sided quantile tests and age of adiposity rebound estimated with curve derivative solutions.</p><p><strong>Results: </strong>A total sample of 8692 visits from 515 patients were used. Growth (height-, weight-, BMI-for-age) channels of CAH patients were significantly different over the entire growing period and characterized by diminished pubertal spurt relative to the CDC reference. Onset of adiposity rebound based on BMI-for-age occurred earlier for CAH patients (females 3.3 years, males 3.9 years) compared to their normative counterparts (5-8 years).</p><p><strong>Conclusion: </strong>Our study showed that at incremental time points throughout childhood, children with CAH collectively follow specific differences in growth trajectories than unaffected children. These variations highlight the need for CAH-specific charts to assist in clinical management, appraisal of growth trajectories and to assess the impact of new therapies.</p>","PeriodicalId":520805,"journal":{"name":"The Journal of clinical endocrinology and metabolism","volume":" ","pages":""},"PeriodicalIF":5.1000,"publicationDate":"2025-10-06","publicationTypes":"Journal Article","fieldsOfStudy":null,"isOpenAccess":false,"openAccessPdf":"","citationCount":"0","resultStr":"{\"title\":\"The Importance of Disease Specific Growth Charts for Children with Congenital Adrenal Hyperplasia.\",\"authors\":\"Kyriakie Sarafoglou, Yesica Mercado Munoz, Charles Sukin, Aida Lteif, Jennifer Kyllo, Bradley S Miller, O Yaw Addo, Deborah Merke\",\"doi\":\"10.1210/clinem/dgaf554\",\"DOIUrl\":null,\"url\":null,\"abstract\":\"<p><strong>Background: </strong>Children with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency typically have height, weight and BMI growth patterns that differ from the general population due to increased androgen and/or glucocorticoid exposures. With the recent surge in the development of new therapies, CAH-specific growth charts are needed to evaluate the effectiveness of these new treatments.</p><p><strong>Methods: </strong>Retrospective data from patients aged 0-20 years with classic CAH, confirmed by hormonal testing and/or CYP21A2 genotyping, from two large clinical databases were analyzed. Specialized charts were developed using the Lamda-Mu-Sigma semi-parametric modeling method to generate CAH-specific percentile curves from 0-20 years. Nodal-point analyses were conducted to assess differences in incremental growth at 4, 8, 12, 16 and 20 years of age relative to CDC-2000 normative charts using one-sided quantile tests and age of adiposity rebound estimated with curve derivative solutions.</p><p><strong>Results: </strong>A total sample of 8692 visits from 515 patients were used. Growth (height-, weight-, BMI-for-age) channels of CAH patients were significantly different over the entire growing period and characterized by diminished pubertal spurt relative to the CDC reference. Onset of adiposity rebound based on BMI-for-age occurred earlier for CAH patients (females 3.3 years, males 3.9 years) compared to their normative counterparts (5-8 years).</p><p><strong>Conclusion: </strong>Our study showed that at incremental time points throughout childhood, children with CAH collectively follow specific differences in growth trajectories than unaffected children. These variations highlight the need for CAH-specific charts to assist in clinical management, appraisal of growth trajectories and to assess the impact of new therapies.</p>\",\"PeriodicalId\":520805,\"journal\":{\"name\":\"The Journal of clinical endocrinology and metabolism\",\"volume\":\" \",\"pages\":\"\"},\"PeriodicalIF\":5.1000,\"publicationDate\":\"2025-10-06\",\"publicationTypes\":\"Journal Article\",\"fieldsOfStudy\":null,\"isOpenAccess\":false,\"openAccessPdf\":\"\",\"citationCount\":\"0\",\"resultStr\":null,\"platform\":\"Semanticscholar\",\"paperid\":null,\"PeriodicalName\":\"The Journal of clinical endocrinology and metabolism\",\"FirstCategoryId\":\"1085\",\"ListUrlMain\":\"https://doi.org/10.1210/clinem/dgaf554\",\"RegionNum\":0,\"RegionCategory\":null,\"ArticlePicture\":[],\"TitleCN\":null,\"AbstractTextCN\":null,\"PMCID\":null,\"EPubDate\":\"\",\"PubModel\":\"\",\"JCR\":\"\",\"JCRName\":\"\",\"Score\":null,\"Total\":0}","platform":"Semanticscholar","paperid":null,"PeriodicalName":"The Journal of clinical endocrinology and metabolism","FirstCategoryId":"1085","ListUrlMain":"https://doi.org/10.1210/clinem/dgaf554","RegionNum":0,"RegionCategory":null,"ArticlePicture":[],"TitleCN":null,"AbstractTextCN":null,"PMCID":null,"EPubDate":"","PubModel":"","JCR":"","JCRName":"","Score":null,"Total":0}
The Importance of Disease Specific Growth Charts for Children with Congenital Adrenal Hyperplasia.
Background: Children with congenital adrenal hyperplasia (CAH) due to 21-hydroxylase deficiency typically have height, weight and BMI growth patterns that differ from the general population due to increased androgen and/or glucocorticoid exposures. With the recent surge in the development of new therapies, CAH-specific growth charts are needed to evaluate the effectiveness of these new treatments.
Methods: Retrospective data from patients aged 0-20 years with classic CAH, confirmed by hormonal testing and/or CYP21A2 genotyping, from two large clinical databases were analyzed. Specialized charts were developed using the Lamda-Mu-Sigma semi-parametric modeling method to generate CAH-specific percentile curves from 0-20 years. Nodal-point analyses were conducted to assess differences in incremental growth at 4, 8, 12, 16 and 20 years of age relative to CDC-2000 normative charts using one-sided quantile tests and age of adiposity rebound estimated with curve derivative solutions.
Results: A total sample of 8692 visits from 515 patients were used. Growth (height-, weight-, BMI-for-age) channels of CAH patients were significantly different over the entire growing period and characterized by diminished pubertal spurt relative to the CDC reference. Onset of adiposity rebound based on BMI-for-age occurred earlier for CAH patients (females 3.3 years, males 3.9 years) compared to their normative counterparts (5-8 years).
Conclusion: Our study showed that at incremental time points throughout childhood, children with CAH collectively follow specific differences in growth trajectories than unaffected children. These variations highlight the need for CAH-specific charts to assist in clinical management, appraisal of growth trajectories and to assess the impact of new therapies.